General Information of the Protein
Protein ID
PT01478
Protein Name
Heat shock protein HSP 90-beta
Secondarily
Protein Name
Heat shock 84 kDa
Gene Name
HSP90AB1
Secondarily
Gene Name
HSP90B
HSPC2
HSPCB
Sequence
MPEEVHHGEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNASDALDKIRYESLTDPSKLDSGKELKIDIIPNPQERTLTLVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVVVITKHNDDEQYAWESSAGGSFTVRADHGEPIGRGTKVILHLKEDQTEYLEERRVKEVVKKHSQFIGYPITLYLEKEREKEISDDEAEEEKGEKEEEDKDDEEKPKIEDVGSDEEDDSGKDKKKKTKKIKEKYIDQEELNKTKPIWTRNPDDITQEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFIPRRAPFDLFENKKKKNNIKLYVRRVFIMDSCDELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNIVKKCLELFSELAEDKENYKKFYEAFSKNLKLGIHEDSTNRRRLSELLRYHTSQSGDEMTSLSEYVSRMKETQKSIYYITGESKEQVANSAFVERVRKRGFEVVYMTEPIDEYCVQQLKEFDGKSLVSVTKEGLELPEDEEEKKKMEESKAKFENLCKLMKEILDKKVEKVTISNRLVSSPCCIVTSTYGWTANMERIMKAQALRDNSTMGYMMAKKHLEINPDHPIVETLRQKAEADKNDKAVKDLVVLLFETALLSSGFSLEDPQTHSNRIYRMIKLGLGIDEDEVAAEEPNAAVPDEIPPLEGDEDASRMEEVD
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Other cytosolic protein
Function
Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (PubMed:16478993, PubMed:19696785). Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself. Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle (PubMed:27295069, PubMed:26991466). Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels. They first alter the steady-state levels of certain transcription factors in response to various physiological cues. Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment. Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression (PubMed:25973397). Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation (PubMed:24613385). Promotes cell differentiation by chaperoning BIRC2 and thereby protecting from auto-ubiquitination and degradation by the proteasomal machinery (PubMed:18239673). Main chaperone involved in the phosphorylation/activation of the STAT1 by chaperoning both JAK2 and PRKCE under heat shock and in turn, activates its own transcription (PubMed:20353823). Involved in the translocation into ERGIC (endoplasmic reticulum-Golgi intermediate compartment) of leaderless cargos (lacking the secretion signal sequence) such as the interleukin 1/IL-1; the translocation process is mediated by the cargo receptor TMED10 (PubMed:32272059).
    Show/Hide
Uniprot ID
Primary ID:
P08238

Secondarily ID:
B2R5P0
Q5T9W7
Q9NQW0
Q9NTK6
    Show/Hide
Ensembl ID
ENSG00000096384
HGNC ID
HGNC:5258
Subcellular Location
Cytoplasm
Melanosome
Nucleus
Secreted
Cell membrane
Dynein axonemal particle
Cell surface
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000679 , AU565
Compound ID Compound Name Compound Formula
CP0423746
1-(2-amino-4-methylquinazolin-7-yl)-3,6,6-trimethyl-5,7-dihydroindol-4-one
   Show/Hide
C20H22N4O
 2
1
IC50 = 4 nM
   TI
   LI
   LO
   TS
2
IC50 = 36 nM
   TI
   LI
   LO
   TS
CP0566920
1-(4-aminoquinazolin-7-yl)-2,3,6,6-tetramethyl-5,7-dihydroindol-4-one
   Show/Hide
C20H22N4O
 1
1
IC50 = 498 nM
   TI
   LI
   LO
   TS
CP0520016
1-(2-aminoquinazolin-7-yl)-3,6,6-trimethyl-5,7-dihydroindol-4-one
   Show/Hide
C19H20N4O
 1
1
IC50 = 705 nM
   TI
   LI
   LO
   TS
CP0489589
1-(4-amino-8-fluoroquinazolin-7-yl)-3,6,6-trimethyl-5,7-dihydroindazol-4-one
   Show/Hide
C18H18FN5O
 1
1
IC50 = 3783 nM
   TI
   LI
   LO
   TS
CP0489588
1-(4-aminoquinazolin-7-yl)-3-ethyl-6,6-dimethyl-5,7-dihydroindazol-4-one
   Show/Hide
C19H21N5O
 1
1
IC50 = 4510 nM
   TI
   LI
   LO
   TS
CP0423745
1-(4-aminoquinazolin-7-yl)-3,6,6-trimethyl-5,7-dihydroindazol-4-one
   Show/Hide
C18H19N5O
 1
1
IC50 = 5813 nM
   TI
   LI
   LO
   TS
CP0566919
1-(4-aminoquinazolin-7-yl)-2,6,6-trimethyl-5,7-dihydroindol-4-one
   Show/Hide
C19H20N4O
 1
1
IC50 = 9974 nM
   TI
   LI
   LO
   TS
CP0495242
1-(2,4-diamino-5-ethylsulfanylquinazolin-7-yl)-3,6,6-trimethyl-5,7-dihydroindol-4-one
   Show/Hide
C21H25N5OS
 1
1
IC50 = 16840 nM
   TI
   LI
   LO
   TS
CP0535553
1-(4-aminoquinazolin-7-yl)-6,6-dimethyl-3-(trifluoromethyl)-5,7-dihydroindazol-4-one
   Show/Hide
C18H16F3N5O
 1
1
IC50 = 16960 nM
   TI
   LI
   LO
   TS
CP0548150
1-(4-amino-5-methoxyquinazolin-7-yl)-3,6,6-trimethyl-5,7-dihydroindol-4-one
   Show/Hide
C20H22N4O2
 1
1
IC50 > 20000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0083379
8-(6-Bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-pent-4-ynyl-9H-purin-6-ylamine
   Show/Hide
C17H14BrN5O2S
 2
1 Activity = 30 nM
2 EC50 = 30 nM
CP0092075
9-{2-[(2,2-dimethylpropyl)amino]ethyl}-8-[(2-iodo-5-methoxyphenyl)sulfanyl]-9H-purin-6-amine
   Show/Hide
C19H25IN6OS
 1
1 Activity = 30 nM
CP0308562
Benzothiazole analogue, 24
   Show/Hide
C18H20ClN6O3PS2
 1
1 Activity = 30 nM
CP0042181
CHEBI:5292
   Show/Hide
C29H40N2O9
 6
1 Activity = 281 nM
2 IC50 = 20 nM
3 IC50 = 22 nM
4 IC50 = 348 nM
5 Kd = 670 nM
6 Kd = 1000 nM
CP0054776
BMS-722782
   Show/Hide
C31H43N3O8
 9
1 Activity = 1270 nM
2 EC50 = 1000 nM
3 IC50 = 7 nM
4 IC50 = 45 nM
5 IC50 = 1270 nM
6 Kd = 7.3 nM
7 Kd = 1300 nM
8 Ki = 9 nM
9 Ki = 530 nM
CP0043495
8-(6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropylamino-propyl)adenine
   Show/Hide
C18H21IN6O2S
 2
1 EC50 = 16 nM
2 IC50 = 42 nM
CP0040552
2-FLUORO-8-[(6-IODO-1,3-BENZODIOXOL-5-YL)METHYL]-9-[3-(ISOPROPYLAMINO)PROPYL]-9H-PURIN-6-AMINE
   Show/Hide
C19H22FIN6O2
 1
1 EC50 = 22 nM
CP0230696
9-butyl-8-(3,4,5-trimethoxybenzyl)-9H-purin-6-amine
   Show/Hide
C19H25N5O3
 1
1 EC50 = 15000 nM
CP0057361
4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide
   Show/Hide
C23H27F3N4O3
 5
1 IC50 = 4 nM
2 IC50 = 7 nM
3 IC50 = 25 nM
4 Ki = 1.1 nM
5 Ki = 2.8 nM
CP0245168
8-cyclopentyl-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C25H30N2O2
 3
1 IC50 = 5 nM
2 IC50 = 6 nM
3 Ki = 5 nM
CP0036286
5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide
   Show/Hide
C26H31N3O5
 9
1 IC50 = 7 nM
2 IC50 = 16 nM
3 IC50 = 21 nM
4 IC50 = 61 nM
5 IC50 = 85 nM
6 Kd = 1.7 nM
7 Ki = 0.064 nM
8 Ki = 0.069 nM
9 Ki = 8.2 nM
CP0060369
2-amino-6-halopurine analogue, 20
   Show/Hide
C14H15ClN6O
 6
1 IC50 = 7 nM
2 IC50 = 17 nM
3 Kd = 1.7 nM
4 Ki = 1.7 nM
5 Ki = 13 nM
6 Ki = 26 nM
CP0656728
Carbamic acid (4E,6Z,10E)-(8S,9S,12S,13R,14S,16R)-19-amino-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-aza-bicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl ester
   Show/Hide
C28H39N3O8
 4
1 IC50 = 7 nM
2 Kd = 100 nM
3 Ki = 3 nM
4 Ki = 21 nM
CP0095063
2,7,7-trimethyl-9-[8-(2-methylpropyl)-1-oxo-3,4-dihydro-2H-isoquinolin-6-yl]-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-5-one
   Show/Hide
C27H35N3O2
 2
1 IC50 = 27 nM
2 Ki = 37 nM
CP0116674
2-fluoro-6-[[(3S)-oxolan-3-yl]amino]-4-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)benzamide
   Show/Hide
C22H26FN3O3
 1
1 IC50 = 30 nM
CP0537806
3-[(3-chlorophenyl)methyl]-6-hydroxy-N-[[4-(methanesulfonamidomethyl)phenyl]methyl]-N-methyl-2H-indazole-5-carboxamide
   Show/Hide
C25H25ClN4O4S
 1
1 IC50 = 60 nM
CP0071055
ALVESPIMYCIN
   Show/Hide
C32H48N4O8
 3
1 IC50 = 90 nM
2 IC50 = 930 nM
3 Kd = 500 nM
CP0166079
6-hydroxy-N-[[4-(methanesulfonamidomethyl)phenyl]methyl]-N-methyl-3-[(3-methylphenyl)methyl]-2H-indazole-5-carboxamide
   Show/Hide
C26H28N4O4S
 1
1 IC50 = 150 nM
CP0078293
N-[(9R)-4-(3H-imidazo[4,5-c]pyridin-2-yl)-9H-fluoren-9-yl]-1H-pyrrolo[2,3-b]pyridine-4-carboxamide
   Show/Hide
C27H18N6O
 1
1 Kd = 0.35 nM
CP0059487
8-(oxan-4-yl)-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C25H30N2O3
 1
1 Ki = 3 nM
CP0340822
8-cyclohexyl-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C26H32N2O2
 1
1 Ki = 5 nM
CP0095064
8-(4-fluorophenyl)-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C26H25FN2O2
 1
1 Ki = 10 nM
CP0157822
2-(cyclopentylamino)-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C26H34N4O2
 1
1 Ki = 12 nM
CP0157827
8-phenyl-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C26H26N2O2
 1
1 Ki = 15 nM
CP0158006
2-(cyclopropylmethylamino)-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C25H32N4O2
 1
1 Ki = 19 nM
CP0116672
8-(3-fluorophenyl)-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C26H25FN2O2
 1
1 Ki = 20 nM
CP0124122
2-(propylamino)-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C24H32N4O2
 1
1 Ki = 21 nM
CP0116671
2-(2,2-dimethylpropylamino)-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C26H36N4O2
 1
1 Ki = 22 nM
CP0366180
2-[(3-methyloxetan-3-yl)methylamino]-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C26H34N4O3
 1
1 Ki = 22 nM
CP0158007
2-(thian-4-ylamino)-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C26H34N4O2S
 1
1 Ki = 25 nM
CP0158008
2-(propan-2-ylamino)-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C24H32N4O2
 1
1 Ki = 25 nM
CP0314115
8-(2-methylpropyl)-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C24H30N2O2
 1
1 Ki = 26 nM
CP0059058
2-(2,2-difluoroethylamino)-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C23H28F2N4O2
 1
1 Ki = 29 nM
CP0095061
2,7,7-trimethyl-9-[1-oxo-8-(propan-2-ylamino)-3,4-dihydro-2H-isoquinolin-6-yl]-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-5-one
   Show/Hide
C26H34N4O2
 1
1 Ki = 30 nM
CP0200791
2-fluoro-6-[[(3S)-oxolan-3-yl]amino]-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C25H31FN4O3
 1
1 Ki = 31 nM
CP0249164
2-[[(3S)-oxolan-3-yl]amino]-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C25H32N4O3
 1
1 Ki = 35 nM
CP0371376
8-cyclobutyl-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C24H28N2O2
 1
1 Ki = 39 nM
CP0116673
8-(4-methoxyphenyl)-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C27H28N2O3
 1
1 Ki = 40 nM
CP0341208
4-(7,7-dimethyl-5-oxo-1,2,3,4,6,8-hexahydrocarbazol-9-yl)-2-[[(3S)-oxolan-3-yl]amino]benzamide
   Show/Hide
C25H31N3O3
 1
1 Ki = 40 nM
CP0178497
2-(cyclopropylamino)-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C24H30N4O2
 1
1 Ki = 48 nM
CP0178496
8-butyl-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C24H30N2O2
 1
1 Ki = 56 nM
CP0366179
2-(2-methoxyethylamino)-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C24H32N4O3
 1
1 Ki = 60 nM
CP0340818
8-benzyl-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C27H28N2O2
 1
1 Ki = 120 nM
CP0059491
8-tert-butyl-6-(3,6,6-trimethyl-4-oxo-5,7-dihydroindol-1-yl)-3,4-dihydro-2H-isoquinolin-1-one
   Show/Hide
C24H30N2O2
 1
1 Ki = 140 nM
CP0340817
2-(2-cyclopropylethyl)-4-(2,7,7-trimethyl-5-oxo-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-9-yl)benzamide
   Show/Hide
C26H33N3O2
 1
1 Ki = 420 nM
CP0173498
2,7,7-trimethyl-9-(1-oxo-3,4-dihydro-2H-isoquinolin-6-yl)-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-5-one
   Show/Hide
C23H27N3O2
 1
1 Ki = 590 nM
CP0173499
2,7,7-trimethyl-9-(1-oxo-2,3,4,5-tetrahydro-2-benzazepin-7-yl)-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-5-one
   Show/Hide
C24H29N3O2
 1
1 Ki > 10000 nM
CP0178493
2,7,7-trimethyl-9-(1-oxo-2,3-dihydroisoindol-5-yl)-3,4,6,8-tetrahydro-1H-pyrido[3,4-b]indol-5-one
   Show/Hide
C22H25N3O2
 1
1 Ki > 10000 nM
Clinical Information about the Protein
Target 1 ( Heat shock protein 90 beta (HSP90B) )
Target Type Clinical trial Target
Disease 1 Target-related Disease  1
1 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Clinical Trial Drug(s) 2 Clinical Trial Drugs  2
1 PU-H71 Phase 1
Solid tumour/cancer
2 TAS-116 Phase 1
Solid tumour/cancer